<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481997</url>
  </required_header>
  <id_info>
    <org_study_id>CET.NIS2020.01</org_study_id>
    <secondary_id>ESR-19-20188</secondary_id>
    <nct_id>NCT04481997</nct_id>
  </id_info>
  <brief_title>Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI</brief_title>
  <acronym>ARTHEMIS</acronym>
  <official_title>Anti-thrombotic and Glucose loweRing THerapy in diabEtics With CAD Undergoing PCI: a Prospective Multicenter observatIonal Study on Their Use and Implications for Clinical Outcomes - The ARTHEMIS Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Centre of the University of Lisbon (CCUL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) is one of the main risk factors for ischemic events in patients with
      coronary artery disease (CAD) and diabetes is a factor in several post-PCI (Percutaneous
      Coronary Intervention) risk scores. However, until recently, there were almost no studies
      performed specifically in the diabetic population of patients undergoing PCI. This study aims
      to describe the anti-thrombotic regimens, clinical outcomes and current diabetes medical
      treatment in an unselected consecutive population of patients with DM undergoing PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is one of the main risk factors for ischemic events in patients with coronary artery
      disease and diabetes is a factor in several post-PCI risk scores (including the commonly used
      DAPT score). However, until recently, there were almost no studies performed specifically in
      the diabetic population of patients undergoing PCI. At large, results from randomized trials
      assessing the duration of DAPT have produced conflicting results and there is uncertainty
      about the best anti-thrombotic strategy in patients with diabetes. Further assessment of the
      patterns of use and their clinical effects, including those related to prolonged DAPT is
      needed, in diabetic patients, especially in less selected &quot;real world&quot; populations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Enumeration of the anti-thrombotic agents prescribed to patients</measure>
    <time_frame>Baseline to 24 months follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Planned duration of dual anti-platelet treatment (DAPT) after the PCI.</measure>
    <time_frame>From index admission to 24 months follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to anti-thrombotic regimen</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
    <description>Classified qualitatively according to the assessment of the attending physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Actual duration of DAPT (if different from the planned duration)</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for interrupting DAPT at a time different from the planned duration</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for prolonging DAPT over 1 year</measure>
    <time_frame>12 to 24 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Coronary Events (MACE)</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
    <description>Major Adverse Coronary Events (MACE) (death from any cause, new spontaneous acute myocardial infarction, stroke).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate from any cause</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular death</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new spontaneous acute myocardial infarction</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital admissions for acute coronary infarction</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unplanned coronary revascularization</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke/transient ischemic attack</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate from heart failure</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital admission due to heart failure</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding events of type 3-5 of BARC (Bleeding Academic Research Consortium) scale</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
    <description>The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will only be collected the events corresponding to type 3-5 of BARC scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding events of type 1-5 of BARC (Bleeding Academic Research Consortium) scale</measure>
    <time_frame>6 to 24 months follow-up</time_frame>
    <description>The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will be collected the events corresponding to type 1-5 of BARC scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients treated with different glucose-lowering drugs.</measure>
    <time_frame>Before index admission to 24 months follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes control (HbA1c values)</measure>
    <time_frame>At baseline to 24 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Diabetic patients with CAD submitted to PCI</arm_group_label>
    <description>Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure to Anti-thrombotic treatment agents and glucose lowering therapy</intervention_name>
    <description>Exposure to Anti-thrombotic treatment agents and glucose lowering therapy</description>
    <arm_group_label>Diabetic patients with CAD submitted to PCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1000 Type 2 Diabetes mellitus consecutive patients submitted to PCI in 12 interventional
        Cardiology Portuguese centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCI with stent implantation, performed in at least one major coronary artery in the
             context of stable coronary artery disease or acute coronary syndrome

          -  Type 2 Diabetes mellitus (previously diagnosed or diagnosed at the index admission)

          -  Informed consent signed

          -  Patient not simultaneously participating in any interventional study

        Exclusion Criteria:

          -  Patients with Type 1 Diabetes mellitus

          -  Patients whose survival is expected to be lower than 1 year at hospital discharge

          -  Patients not whiling to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sérgio B Baptista, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Centre of the University of Lisbon (CCUL)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luís Raposo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Santa Cruz, CHLO, EPE, Lisbon, Portugal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sérgio B Baptista, PhD</last_name>
    <phone>+351 962364061</phone>
    <email>sergio.b.baptista@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luís Raposo, MD</last_name>
    <phone>+351 962933777</phone>
    <email>lfor.md@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Prof. Doutor Fernando Fonseca</name>
      <address>
        <city>Amadora</city>
        <state>Lisbon</state>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Sérgio B Baptista, PhD</last_name>
      <phone>+351 962364061</phone>
      <email>Sergio.b.baptista@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Ocidental - Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <state>Lisbon</state>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Luís Raposo, MD</last_name>
      <phone>+351 962933777</phone>
      <email>lfor.md@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Central - Hospital de Santa Marta</name>
      <address>
        <city>Lisboa</city>
        <state>Lisbon</state>
        <zip>1159-064</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Luís Morais, MD</last_name>
      <phone>+351 918387594</phone>
      <email>Lmmorais88@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <state>Lisbon</state>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro C Ferreira, MD</last_name>
      <phone>+351 966412473</phone>
      <email>pcarrilhoferreira@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <state>Porto</state>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Gustavo P Morais, MD</last_name>
      <phone>+351 936 111 773</phone>
      <email>gpmorais@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <state>Setúbal</state>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Cristina Martins, MD</last_name>
      <phone>+351 917 641 056</phone>
      <email>cristinamartins64@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga, EPE</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>João Costa, MD</last_name>
      <phone>+351 917 219 525</phone>
      <email>jfscosta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra - Hospital Geral &amp; Hospital Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Algarve - Hospital de Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Hugo Vinhas, MD</last_name>
      <phone>+351 965813045</phone>
      <email>hugo.vinhas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>André Luz, MD</last_name>
      <phone>+351 918 167 095</phone>
      <email>andrecoimbraluz@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Setúbal</name>
      <address>
        <city>Setúbal</city>
        <zip>2910-549</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Filipe Seixo, MD</last_name>
      <phone>+351 933261150</phone>
      <email>fseixo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Espírito Santo de Évora, EPE</name>
      <address>
        <city>Évora</city>
        <zip>7000-811</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Diogo Brás, MD</last_name>
      <phone>+351 912 757 667</phone>
      <email>diogobras8@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCI-Percutaneous Coronary Intervention</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Dual Antiplatelet Therapy</keyword>
  <keyword>Anti-diabetic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

